Drug pipelines are thick with novel compounds that may have an effect on our most insidious diseases.  However, most either fail early trials or are withdrawn because companies don’t see the return on investment of driving them forward. These shelved compounds still may have important roles in treating orphan diseases.  The Children’s Tumor Foundation identifies these compounds lost to corporate expectations and re-analyzes them for therapeutic potential for other indications. Dr. Annette Bakker describes the process, the potential and the promise of compounds already identified in this partnership with pharmaceutical companies– testing their throwaways for new applications.# COLABRATalking Biotech is brought to you by Colabra – an R&D platform that brings your lab’s world-changing research together in one shared space. Learn more at https://www.colabra.app/# TALKING BIOTECHTwitter: https://twitter.com/talkingbiotechWebsite: https://www.colabra.app/podcasts/talking-biotech/Instagram: https://www.instagram.com/colabrahqThe Talking Biotech podcast is distinct from Dr. Kevin Folta's teaching and research roles at the University of Florida. The views expressed on the show are those of Dr. Folta and his guests, and do not reflect the opinions of the university or Colabra.